Methods and compositions for overcoming immunosuppression

US11739156B2 · kind B2 · utility

Assignee

• The Broad Institute, Inc. Massachusetts Institute of Technology · US

Inventors

• Amy Li · Cambridge, US
• Rebecca H. Herbst · Cambridge, US
• Aviv Regev · Cambridge, US
• Tyler E. Jacks · Newton, US
• David A. Canner · Cambridge, US

Key dates

• Filing date: Jan 6, 2020
• Grant date: Aug 29, 2023
• Expiry date: Oct 3, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/732
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention discloses novel methods, compositions, and uses thereof for removing or overcoming immunosuppression. More specifically, the methods and compositions disclosed herein target effector Treg cells by modulating ST2 and/or IL-33 signaling using pharmaceutical inhibitors and/or genetic ablation, whereby the levels and/or activities of effector Treg cells in a tumor microenvironment are inhibited, and the infiltration of effector CD8+ cytotoxic T cells into tumor microenvironment increases. As a result, tumor growth is inhibited and tumor volume is reduced. The present invention also provides methods for identifying and isolating effector Treg cells in a population of heterogeneous cells.